| P50 | author | Caterina P Profaci | Q83426085 |
| P2093 | author name string | Joseph H Neale | |
| | Rafal T Olszewski | |
| | Kristyn A Krolikowski | |
| P2860 | cites work | Molecular cloning of a peptidase against N-acetylaspartylglutamate from a rat hippocampal cDNA library | Q24309190 |
| | N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system | Q28141091 |
| | Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review | Q28215767 |
| | Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies | Q28215775 |
| | Mouse genetic models for prepulse inhibition: an early review | Q28217163 |
| | Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR | Q28238132 |
| | The neuroactive peptide N-acetylaspartylglutamate is not an agonist at the metabotropic glutamate receptor subtype 3 of metabotropic glutamate receptor | Q28242378 |
| | Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain - relation to brain concentration | Q28259391 |
| | The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia | Q28264674 |
| | Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats | Q28280906 |
| | Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats | Q28284443 |
| | Regulation of neurotransmitter release by metabotropic glutamate receptors | Q28506056 |
| | Molecular identification of N-acetylaspartylglutamate synthase and beta-citrylglutamate synthase | Q28506479 |
| | Isolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase II | Q28572589 |
| | The cloning and characterization of a second brain enzyme with NAAG peptidase activity | Q28589768 |
| | Molecular characterization of N-acetylaspartylglutamate synthetase | Q28592468 |
| | Recent advances in the phencyclidine model of schizophrenia | Q29618917 |
| | Effect of d-amphetamine on prepulse inhibition of the startle reflex in humans. | Q51089700 |
| | On the influence of baseline startle reactivity on the indexation of prepulse inhibition. | Q51950318 |
| | The effects of atypical antipsychotics and phencyclidine (PCP) on rotorod performance. | Q52535861 |
| | The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats | Q73002699 |
| | Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury | Q73226156 |
| | The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing | Q74317098 |
| | Heritability of acoustic startle magnitude, prepulse inhibition, and startle latency in schizophrenia and control families | Q30474699 |
| | Stability of inbred mouse strain differences in behavior and brain size between laboratories and across decades | Q30478159 |
| | Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors | Q30491856 |
| | Relationship between PPI and baseline startle response | Q30494338 |
| | NAAG inhibits KCl-induced [(3)H]-GABA release via mGluR3, cAMP, PKA and L-type calcium conductance | Q31900140 |
| | Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase | Q33576278 |
| | GCP II (NAALADase) inhibition suppresses mossy fiber-CA3 synaptic neurotransmission by a presynaptic mechanism | Q33606875 |
| | LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine | Q33889339 |
| | Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine | Q33912479 |
| | G protein specificity: traffic direction required. | Q34117298 |
| | A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity | Q34445862 |
| | Presynaptic group II metabotropic glutamate receptors reduce stimulated and spontaneous transmitter release in human dentate gyrus | Q34521682 |
| | Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia | Q34534020 |
| | Animal behavior models of the mechanisms underlying antipsychotic atypicality | Q35595230 |
| | Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions | Q36756365 |
| | Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia | Q37341995 |
| | Characterization of pharmacological and behavioral differences to nicotine in C57Bl/6 and DBA/2 mice | Q37365956 |
| | Sensing G protein-coupled receptor activation. | Q37781423 |
| | Type 2 metabotropic glutamate receptor (mGluR2) fails to negatively couple to cGMP in stably transfected cells | Q39626308 |
| | The phencyclidine-glutamate model of schizophrenia. | Q40989392 |
| | Endogenous N-acetylaspartylglutamate (NAAG) inhibits synaptic plasticity/transmission in the amygdala in a mouse inflammatory pain model. | Q42065018 |
| | Intracerebroventricular administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in inflammatory pain | Q42397202 |
| | Metabotropic glutamate receptors modulate glutamatergic and GABAergic synaptic transmission in the central nucleus of the inferior colliculus | Q43162938 |
| | beta-NAAG rescues LTP from blockade by NAAG in rat dentate gyrus via the type 3 metabotropic glutamate receptor | Q43541808 |
| | Spinal N-acetyl-alpha-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat. | Q43691638 |
| | Involvement of metabotropic glutamate receptors in excitatory amino acid and GABA release following spinal cord injury in rat. | Q43809095 |
| | Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate | Q44163112 |
| | Growth hormone-induced diacylglycerol and ceramide formation via Galpha i3 and Gbeta gamma in GH4 pituitary cells. Potentiation by dopamine-D2 receptor activation | Q44177171 |
| | The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity | Q44278062 |
| | Assessment of murine startle reactivity, prepulse inhibition, and habituation | Q44391778 |
| | Epinephrine activates both Gs and Gi pathways, but norepinephrine activates only the Gs pathway through human beta2-adrenoceptors overexpressed in mouse heart | Q44854966 |
| | NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. | Q44893918 |
| | Serotonin transporter, 5-HT1A receptor, and behavior in DBA/2J mice in comparison with four inbred mouse strains. | Q45965966 |
| | NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat. | Q46142561 |
| | Interstrain differences in the content of excitatory and inhibitory amino acids in the brain of DBA/2J, Balb/c and C57BL/6 mice: characteristics of the effect of a dipeptide antipsychotic drug dilept | Q46345207 |
| | Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. | Q46634081 |
| | Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). | Q46634848 |
| | First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients | Q46724711 |
| | Differential negative coupling of type 3 metabotropic glutamate receptor to cyclic GMP levels in neurons and astrocytes | Q46897516 |
| | Use of MGLUR2 and MGLUR3 knockout mice to explore in vivo receptor specificity of the MGLUR2/3 selective antagonist LY341495. | Q47705855 |
| | Effects of the mGluR2/3 agonist LY379268 on ketamine-evoked behaviours and neurochemical changes in the dentate gyrus of the rat. | Q48466827 |
| P433 | issue | 2 | |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 235-243 | |
| P577 | publication date | 2011-02-16 | |
| P1433 | published in | Psychopharmacology | Q1422802 |
| P1476 | title | Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia | |
| P478 | volume | 216 | |